机构：[1]Peking University First Hospital, Beijing 100034, China[2]Shandong Provincial Hospital, Jinan 250021, China[3]Guangdong General Hospital, Guangzhou 510008, China广东省人民医院[4]The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China[5]The First Hospital, Shanxi Medical University, Taiyuan 030001, China[6]Xiangya Hospital, Central South University, Changsha 410008, China[7]General Hospital of PLA, Beijing 100853, China[8]The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China[9]Guizhou Provincial People’s Hospital, Guiyang 550002, China[10]Jiangxi Province Children’s Hospital, Nanchang 330006, China[11]Fourth Hospital of Hebei Medical University, Shijiazhuang 050019, China河北医科大学第四医院[12]Jiangsu Province Hospital, Nanjing 210029, China江苏省人民医院[13]Peking University People’s Hospital, Beijing 100044, China[14]The First Affiliated Hospital of XinjiangMedical University, Urumqi 830054, China[15]Inner Mongolia People’s Hospital, Hohhot 010017, China[16]Heilongjiang Province Center for Disease Control and Prevention, Harbin 150030, China
Healthcare associated infection (HAI) is known to increase the economic burden of patients while the medical cost due to MDRO HAI is even higher. Three hundred eighty-one multidrug resistance organisms (MDROs) healthcare associated infection (HAI) case-patients and three hundred eighty-one matched control-patients were identified between January and December in 2015. The average total hospitalization medical cost of the case group was $6127.65 and that of the control group was $2274.02. The difference between the case group and the control group was statistically significant (t = 21.07; P < 0.01). The attributable cost of MDRO HAI was $3853.63. The direct medical costs due to different MDRO infections were different. The increased medical costs of CR-AB, CR-KP, and CR-PA were significantly higher than that of MRSA, MRSE, ESBL E. coli, and ESBL Kp (P < 0. 05). Among the subitem expenses, the drug cost increased the most (the average cost was $1457.72), followed by the treatment fee and test fee; the differences were statistically significant (P < 0.01).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2019]版：
大类|3 区生物
小类|3 区生物工程与应用微生物4 区医学：研究与实验
最新[2025]版：
大类|4 区医学
小类|4 区生物工程与应用微生物4 区医学：研究与实验
JCR分区：
出版当年[2019]版：
Q3BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ3MEDICINE, RESEARCH & EXPERIMENTAL
最新[2024]版：
Q3BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ3MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构：[1]Peking University First Hospital, Beijing 100034, China
通讯作者：
推荐引用方式(GB/T 7714)：
Jia Huixue,Li Weiguang,Hou Tieying,et al.The Attributable Direct Medical Cost of Healthcare Associated Infection Caused by Multidrug Resistance Organisms in 68 Hospitals of China[J].BIOMED RESEARCH INTERNATIONAL.2019,2019:doi:10.1155/2019/7634528.
APA：
Jia, Huixue,Li, Weiguang,Hou, Tieying,Ma, Hongqiu,Yang, Yun...&Li, Liuyi.(2019).The Attributable Direct Medical Cost of Healthcare Associated Infection Caused by Multidrug Resistance Organisms in 68 Hospitals of China.BIOMED RESEARCH INTERNATIONAL,2019,
MLA：
Jia, Huixue,et al."The Attributable Direct Medical Cost of Healthcare Associated Infection Caused by Multidrug Resistance Organisms in 68 Hospitals of China".BIOMED RESEARCH INTERNATIONAL 2019.(2019)
